Glenmark Pharmaceuticals has announced that it plans to commence shipping of oral contraceptive drug, drospirenone and ethinyl estradiol tablet, immediately following the grant of final approval for the product from the United States Food & Drug Administration (US FDA). The oral contraceptive is a generic version of Bayer Healthcare Pharmaceuticals' Yaz tablet.
"Glenmark Pharmaceuticals Inc, USA has been granted final approval by US FDA for drospirenone and ethinyl estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing on August 19, 2015.
According to IMS Health sales data, Yaz market achieved annual sales of approximately $170.1 million for the 12 months period ending June 2015.
"Glenmark Pharmaceuticals Inc, USA has been granted final approval by US FDA for drospirenone and ethinyl estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing on August 19, 2015.
According to IMS Health sales data, Yaz market achieved annual sales of approximately $170.1 million for the 12 months period ending June 2015.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%